<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01990482</url>
  </required_header>
  <id_info>
    <org_study_id>gungorduk15</org_study_id>
    <nct_id>NCT01990482</nct_id>
  </id_info>
  <brief_title>Influence of Coffee Intake on Postoperative Bowel Function After Comprehensive Staging Surgery for Gynecological Malignancies: A Randomized Controlled Trial.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erzincan Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erzincan Military Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Turkey: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A delay in the return of normal bowel function with the passage of flatus and feces is one
      of the most important factors affecting early recovery and discharge in patients undergoing
      open complete staging surgery for gynecological malignancies. A prolonged hospital stay
      increases the risk of hospital-acquired infections, deep vein thrombosis, pulmonary
      compromise and total hospital costs.

      The aim of this study was to assess the effectiveness of coffee intake on postoperative
      bowel function in patients undergoing abdominal complete staging surgery for gynecological
      malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>time to first flatus</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hours from end of operation to first flatus pass time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to tolerance diet</measure>
    <time_frame>within the first 30 days  after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>time to end of the surgery  until the first solid diet intake without vomiting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Ilues</condition>
  <arm_group>
    <arm_group_label>coffee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>water group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>caffe</intervention_name>
    <arm_group_label>coffee</arm_group_label>
    <arm_group_label>water group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water</intervention_name>
    <arm_group_label>coffee</arm_group_label>
    <arm_group_label>water group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients preparing for complete surgical staging for malignant gynecologic
             disease such as endometrial cancer, cervix cancer and ovarian cancerwere assessed for
             eligibility. Exclusion Criteria: Exclusion criteria for the study

          -  included thyroid diseases,

          -  inflammatory bowel disease,

          -  complaints of chronic constipation (defined as two or fewer bowel movements per
             week),

          -  a history of prior abdominal bowel surgery,  abdominal radiation, neoadjuvant
             chemotherapy,

          -  need for intensive care more that 24 hpostoperatively,

          -  nasogastric tube drainage beyond the first postoperative morning,

          -  bowel anastomosis and upper abdominalmultivisceral surgical approaches in relation to
             the debulking surgery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kemal Gungorduk, M.D.</last_name>
    <phone>90 0505 492 71 66</phone>
    <email>maidenkemal@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aykut Ozdemir, M.D.</last_name>
    <phone>90 0505 795 111 58</phone>
    <email>isaaykutozdemir@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tepecik Education Research Hospital</name>
      <address>
        <city>Izmir</city>
        <state>Tepecik</state>
        <zip>35600</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mehmet gokcu, MD</last_name>
      <phone>90 0532 478 54 57</phone>
      <email>gokcumehmet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kemal Gungorduk, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 17, 2013</lastchanged_date>
  <firstreceived_date>November 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erzincan Military Hospital</investigator_affiliation>
    <investigator_full_name>Kemal GUNGORDUK</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
